All > Bladder Cancer

AMVAC + Nivolumab for Bladder Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Bladder CancerAMVAC + Nivolumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new combination of drugs to treat bladder cancer. If it is successful, it could help people preserve their Bladders and avoid surgery.

Eligible Conditions
  • Bladder Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Treatment (CB-839 HCl, sapanisertib)
1
AU-011
1
TARA-002

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: up to 5 years

2 years
Incidence of Metastasis-free survival (MFS)
Day 100
Number of patients erporting Toxicity of neoadjuvant nivolumab and AMVAC therapy
up to 5 years
Number of days of Overall survival
Number of days of Progression free survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Treatment (CB-839 HCl, sapanisertib)
1
AU-011
1
TARA-002

Trial Design

1 Treatment Group

AMVAC + nivolumab
1 of 1

Experimental Treatment

71 Total Participants · 1 Treatment Group

Primary Treatment: AMVAC + Nivolumab · No Placebo Group · Phase 2

AMVAC + nivolumab
Drug
Experimental Group · 1 Intervention: AMVAC + Nivolumab · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor
215 Previous Clinical Trials
33,451 Total Patients Enrolled
Pooja Ghatalia, MDPrincipal InvestigatorFox Chase Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are male or female and are 18 years of age or older.
You have no radiographic evidence of lymph node positive disease as per RECIST 1.1 (≥15 mm short axis diameter)
Urothelial carcinoma of the prostatic urethra in men is allowed.
The muscularis propria is invaded.
Left ventricular ejection fraction ≥ 50% by MUGA or ECHO within 6 months of study entry.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top